Table 1 Patient characteristics
|  | Patients (n = 100) |
|---|---|
Age (years), median (range) | 51 (24–69) |
  < 65, n (%) | 93 (93.0) |
  ≥ 65, n (%) | 7 (7.0) |
ECOG performance status, n (%) | |
 0 | 29 (29.0) |
 1 | 71 (71.0) |
Hormone receptor status, n (%) | |
 ER and/or PgR positive | 35 (35.0) |
 ER and PgR negative | 65 (65.0) |
Disease stage, n (%) | |
 III | 6 (6.0) |
 IV | 94 (94.0) |
Visceral metastases, n (%) | 66 (66.0) |
Non-visceral metastases, n (%) | 34 (34.0) |
Site of metastases, n (%) | |
 Brain | 4 (4.0) |
 Lung | 45 (45.0) |
 Liver | 28 (28.0) |
 Bone | 20 (20.0) |
 Lymph nodes | 58 (58.0) |
 Others | 45 (45.0) |
Primary trastuzumab resistance, n (%) | |
 Progression during adjuvant trastuzumab | 21 (21.0) |
 Progression within 12 months of completing adjuvant trastuzumab | 49 (49.0) |
 Progression within 6 months after initiation of first-line trastuzumab for advanced disease | 30 (30.0) |
Prior anti-HER2 therapy, n (%) | |
 Trastuzumab | 100 (100) |
 Pertuzumab | 21 (21.0) |
 BAT8001 | 2 (2.0) |
Prior chemotherapy, n (%) | |
 Taxane | 96 (96.0) |
 Anthracycline | 79 (79.0) |
 Cyclophosphamide | 79 (79.0) |
 Platinum | 22 (22.0) |
 Capecitabine | 6 (6.0) |
Prior lines of chemotherapy for advanced disease, n (%) | |
 0 | 66 (66.0) |
 1 | 32 (32.0) |
 2 | 2 (2.0) |